Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers.

@article{Nam2015PharmacokineticCO,
  title={Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers.},
  author={Jung Hyun Nam and Minkyung Oh and Hyun Ji Kim and Sungpil Han and Eun Ji Kim and Geun Seog Song and Eun-Young Kim and Jae-Gook Shin and Jong-Lyul Ghim and Ho-Sook Kim},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2015},
  volume={53 1},
  pages={
          66-74
        }
}
  • J. Nam, M. Oh, Ho-Sook Kim
  • Published 2015
  • Medicine
  • International journal of clinical pharmacology and therapeutics
The aim of this study was to compare pharmacokinetic characteristics of fixed-dose combination (FDC) of two different salt form of amlodipine, amlodipine adipate/valsartan and amlodipine besylate/ valsartan, in healthy Korean volunteers under fasting conditions. A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 14-day wash-out period was conducted. Plasma samples were collected for up to 144 hours for amlodipine and 24 hours for valsartan. Plasma… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 22 REFERENCES
Amlodipine/Valsartan
TLDR
Subgroup analyses of data from the two trials showed that the antihypertensive efficacy of amlodipine/valsartan in the elderly, Black patients and those with stage 2 hypertension was consistent with that observed in the overall study population.
Clinical Pharmacokinetics of Amlodipine
TLDR
Although structurally related to other dihydropyridine derivatives, amlodipine displays significantly different pharmacokinetic characteristics and is suitable for administration in a single daily dose.
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
TLDR
Valsartan provides a new antihypertensive agent with comparable efficacy to lisinopril and appears to be associated with a reduced incidence of cough.
Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms
  • P. Meredith
  • Medicine
    Current medical research and opinion
  • 2009
TLDR
The validity of the current criteria for interchangeability of generic and innovator drugs remains controversial and may compromise the response and/or safety of patients.
Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis
TLDR
Compared with free-drug combinations, FDCs of antihypertensive agents are associated with a significant improvement in compliance and with nonsignificant beneficial trends in BP and adverse effects.
Clinical Pharmacology and Biopharmaceutics
TLDR
The open access principle brings forth rapid and free access to innovative research outcomes via this journal to enable scientists to obtain a comprehensive profile of the physicochemical, biopharmaceutical and clinical principles, and the delivery potential and challenges of a drug.
Rationale for Fixed-Dose Combinations in the Treatment of Hypertension
TLDR
Fixed-dose combination therapy has a proven record of reducing BP and if made truly cost-competitive, it will gain an increasing share of the hypertensive market if not, market forces will relegate it to a secondary role for hypertension treatment.
...
...